Free Newsletter
Success in traveler's diarrhea jab trial
A new study published in Infection and Immunity says that an experimental vaccine against C. jejune, a major cause of traveler's diarrhea, worked to protect mice and monkeys in a clinical study and may well prove effective in humans as well.
"We are very excited about these results," says Dr. Patricia Guerry, the senior investigator. C. jejune also plays a role in other ailments, such as inflammatory bowel disease. Guerry has been working with grant money from the National Institute of Allergy and Infectious Diseases.
In particular, Guerry noted that monkeys were completely protected from diarrhea caused by C. jejune. Traveler's diarrhea is a common ailment for Americans journeying abroad, and it has inspired several development programs by biotech companies.
- read the story from Reuters
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: